|
|
Volumn 64, Issue 10, 2008, Pages 1033-1035
|
|
No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYTOCHROME P450 3A5;
MIDAZOLAM;
CYP3A5 PROTEIN, HUMAN;
CYTOCHROME P450 3A;
UNCLASSIFIED DRUG;
ADULT;
CONTROLLED STUDY;
CYP3A5 GENE;
DRUG ABSORPTION;
DRUG BIOAVAILABILITY;
DRUG CLEARANCE;
DRUG METABOLISM;
ENZYME ACTIVITY;
GENE;
GENETIC POLYMORPHISM;
GENOTYPE;
HUMAN;
HUMAN EXPERIMENT;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
INTESTINE;
LETTER;
LIQUID CHROMATOGRAPHY;
LIVER;
MALE;
MAXIMUM PLASMA CONCENTRATION;
NORMAL HUMAN;
PHENOTYPE;
PRIORITY JOURNAL;
TANDEM MASS SPECTROMETRY;
BIOAVAILABILITY;
BLOOD;
CASE CONTROL STUDY;
FEMALE;
GENETICS;
INTRAVENOUS DRUG ADMINISTRATION;
METABOLIC CLEARANCE RATE;
METABOLISM;
MIDDLE AGED;
ORAL DRUG ADMINISTRATION;
ADMINISTRATION, ORAL;
ADULT;
BIOLOGICAL AVAILABILITY;
CASE-CONTROL STUDIES;
CYTOCHROME P-450 CYP3A;
FEMALE;
HIV INFECTIONS;
HIV SEROPOSITIVITY;
HUMANS;
INJECTIONS, INTRAVENOUS;
INTESTINES;
LIVER;
MALE;
METABOLIC CLEARANCE RATE;
MIDAZOLAM;
MIDDLE AGED;
POLYMORPHISM, GENETIC;
|
|
EID: 53249129094
PISSN: 00316970
EISSN: None
Source Type: Journal
DOI: 10.1007/s00228-008-0503-9 Document Type: Letter |
|
Times cited : (16)
|
|
References (3)
|
